Dr Asim Joshi

Research Scientist

Asim Joshi has completed his PhD from The Advanced Centre for Treatment, Research and Education in Cancer (ACTREC) - Tata Memorial Center. He has worked extensively in identifying genetic alterations that contribute to cancer development and therapeutic resistance. He has authored multiple peer reviewed research articles and has presented his work at various scientific conferences. His research interests include cancer genomics and development of novel and innovative cancer diagnostics.

Selected Publications

  1. Joshi A*, Butle A*, Hait S, Mishra R, Trivedi V, Thorat R, Choughule A, Noronha V, Prabhash K, Dutt A. Osimertinib for lung cancer cells harboring low-frequency EGFR T790M mutation. Transl Oncol. 2022 Aug;22:101461. doi: 10.1016/j.tranon.2022.101461. Epub 2022 May 30. PMID: 35653897; PMCID: PMC9156817.
  2. Joshi A*, Mishra R, Desai S, Chandrani P, Kore H, Sunder R, Hait S, Iyer P, Trivedi V, Choughule A, Noronha V, Joshi A, Patil V, Menon N, Kumar R, Prabhash K, Dutt A. Molecular characterization of lung squamous cell carcinoma tumors reveals therapeutically relevant alterations. Oncotarget. 2021 Mar 16;12(6):578-588. doi: 10.18632/oncotarget.27905. PMID: 33796225; PMCID: PMC7984830.
  3. Butle A*, Joshi A*, Noronha V, Prabhash K, Dutt A. Weekly osimertinib dosing prevents EGFR mutant tumor cells destined to home mouse lungs. Transl Oncol. 2021 Aug;14(8):101111. doi: 10.1016/j.tranon.2021.101111. Epub 2021 May 13. PMID: 33993094; PMCID: PMC8236545.
  4. Desai S, Mishra SV, Joshi A*, Sarkar D, Hole A, Mishra R, Dutt S, Chilakapati MK, Gupta S, Dutt A. Raman spectroscopy-based detection of RNA viruses in saliva: A preliminary report. J Biophotonics. 2020 Oct;13(10):e202000189. doi: 10.1002/jbio.202000189. Epub 2020 Aug 10. PMID: 32609429; PMCID: PMC7361326.
  5. Iyer P, Shrikhande SV, Ranjan M, Joshi A*, Gardi N, Prasad R, Dharavath B, Thorat R, Salunkhe S, Sahoo B, Chandrani P, Kore H, Mohanty B, Chaudhari V, Choughule A, Kawle D, Chaudhari P, Ingle A, Banavali S, Gera P, Ramadwar MR, Prabhash K, Barreto SG, Dutt S, Dutt A. ERBB2 and KRAS alterations mediate response to EGFR inhibitors in early stage gallbladder cancer. Int J Cancer. 2019 Apr 15;144(8):2008-2019. doi: 10.1002/ijc.31916. Epub 2018 Dec 8. PMID: 30304546; PMCID: PMC6378102.